Health sciences

Aurora Spine Corporation Announces FDA 510(k) Clearance for DEXA-C™ Cervical Interbody System

Retrieved on: 
Tuesday, August 3, 2021
Prosthetics, Medicine, Spine, Implant, Minimally invasive procedure, Forward-looking statement, Health sciences, Life sciences

Mr. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated, "This approval is the first of its kind in the world by offering an implant based upon a patient's bone density.

Key Points: 
  • Mr. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated, "This approval is the first of its kind in the world by offering an implant based upon a patient's bone density.
  • Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
  • Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release.
  • These statements speak only as of the date of this press release, and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Health, Pharmaceutical industry, Pharmacology, Pharmacy, Health care quality, Clinical trials, Clinical research

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today reported financial results for the second quarter and six months ended June 30, 2021. The company also announced key enrollment milestone achievements for its lead product candidate, mavorixafor, a novel, oral small molecule currently being evaluated in a Phase 3 clinical trial (4WHIM) for patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and in two Phase 1b clinical trials for patients with Waldenström’s macroglobulinemia and Severe Congenital Neutropenia (SCN) and chronic neutropenia disorders, respectively.

Key Points: 
  • We are very encouraged by the strong interest from both the physicians and patients participating in our mavorixafor clinical programs, said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • We look forward to reporting on our continued progress with mavorixafor, presenting additional clinical, pre-clinical and prevalence data, and providing a variety of company updates later this year.
  • Enrollment will be completed in the third quarter of 2021, allowing the remaining identified patients to complete screening and potential enrollment.
  • X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Hallucinations, Psychedelic drugs, Entheogens, Psilocybin, Pharmaceutical industry, Psychoactive drugs, Pharmaceutical sciences

During the interview, Klaff asked why the company focuses on psychedelics, how McKee got involved with Tryp and what opportunities the company sees in the psychedelics space.

Key Points: 
  • During the interview, Klaff asked why the company focuses on psychedelics, how McKee got involved with Tryp and what opportunities the company sees in the psychedelics space.
  • There are a lot of naturally derived chemistries around that eventually find their way into more traditional drug development pathways.
  • Since then, several respected academics at NYU, Johns Hopkins, Yale University and others have been studying these compounds.
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

MMIT Announces Sixth-Annual Specialty Pharmacy Patient Choice Awards

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Articles, Health, Specialty drugs, Specialty pharmacy, Health care quality, Patient satisfaction, Pharmacy, Net promoter score, Customer satisfaction

Yardley, PA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner solely focused on solving the what and why of market accessso that patients dont face delays when trying to access lifesaving drugshas announced the finalists of the sixth-annual Specialty Pharmacy Patient Choice Awardsbased on patient satisfaction survey results from the previous year.

Key Points: 
  • Yardley, PA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner solely focused on solving the what and why of market accessso that patients dont face delays when trying to access lifesaving drugshas announced the finalists of the sixth-annual Specialty Pharmacy Patient Choice Awardsbased on patient satisfaction survey results from the previous year.
  • Each year, MMIT recognizes specialty pharmacies that provide best-in-class customer satisfaction and overall patient care within four categories: Payer/PBM, Hospital and Health System, Independent and Retail.
  • The finalists and winners are calculated based on the highest average Net Promoter Score (NPS) from the Zitter Insights Specialty Pharmacy Patient Satisfaction Survey, which provides clients with data they can trust to help them improve patient satisfaction and increase scripts.
  • Were thrilled to once again recognize those who are leading the pack in the specialty pharmacy industry, said MMIT CEO Mike Gallup.

GoodRx Savings Increase Pharmacy Visits and Customer Loyalty For Retailers

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Health, Pharmacy, Pharmaceuticals policy, GoodRx, Telemedicine, Drugs, Prescription drug

Findings indicate that GoodRx helps pharmacies boost sales by driving in-store foot traffic, improving customer loyalty, and increasing medication affordability and access for their customers.

Key Points: 
  • Findings indicate that GoodRx helps pharmacies boost sales by driving in-store foot traffic, improving customer loyalty, and increasing medication affordability and access for their customers.
  • For those looking for even greater discounts, GoodRx offers a subscription savings program, GoodRx Gold , which provides savings of up to 90% off the pharmacy retail (or usual and customary) price on prescription drugs at participating pharmacies nationwide.
  • Encourage pharmacy loyalty among customers: 85% of consumers surveyed agree that their positive experience with GoodRx makes them want to return to their pharmacy.
  • 65% of consumers who use GoodRx reported visiting their pharmacy at least once a month, with 26% making additional trips because of GoodRx.

Pharmaceutics International, Inc. (Pii) to Platform West Pharmaceutical Services, Inc.’s Daikyo Crystal Zenith® Container-Closure Components for Aseptic Fill-Finish

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical industry, Health sciences, Life sciences, Syringe, Fill and finish, Contract manufacturing organization, Health care

Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.

Key Points: 
  • Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.
  • Piis initial implementation will be filling ready-to-use (RU) syringes and cartridges in its aseptic fill-finish processes.
  • We are a trusted partner to the worlds top pharmaceutical and biotechnology companiesworking by their side to improve patient health.
  • Crystal Zenith technology is licensed to West Pharmaceutical Services, Inc. from Daikyo Seiko, Ltd.

Global Biological Safety Testing Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Other Health, Health, Science, Other Science, Health sciences, Pharmacy, Health, Articles, COVID-19 pandemic, Occupational safety and health, Pandemics, Public Health Emergency of International Concern, Biotechnology, Bioburden, Pharmaceutical industry

Bioburden Testing Segment is expected to hold a significant share in the test segment of the market over the forecast period.

Key Points: 
  • Bioburden Testing Segment is expected to hold a significant share in the test segment of the market over the forecast period.
  • Further, the development of new products in the market is expected to accelerate the market studied.
  • Due to the outbreak of COVID-19, the rising R&D activities related to the COVID-19 have impacted positively on the market growth.
  • The growth of the biological safety testing market in this region can be directly attributed to the growing biotechnology and pharmaceutical industries in the region.

Contract Research Organization Services Market by Type, Therapeutic Area, Molecule Type, End-user - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Science, Health, Research, Life sciences, Health sciences, Clinical research, Pharmaceutical industry, Pharmaceuticals policy, Articles, Biotechnology, Contract research organizations, ICON plc

The "Global Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Laboratory), Therapeutic Area (Oncology, Infectious Disease), Molecule Type (Vaccine, CGT), End User (Pharma, Biopharma, Research Institute) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Laboratory), Therapeutic Area (Oncology, Infectious Disease), Molecule Type (Vaccine, CGT), End User (Pharma, Biopharma, Research Institute) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The contract research organization (CRO) services market by type is categorized into major early-phase services, clinical research services, laboratory services, and consulting services.
  • Asia Pacific: The fastest-growing region in the contract research organization (CRO) services market.
  • North America accounted for the largest share of the contract research organization (CRO) services market.

AscellaHealth and Appro-Rx Partner to Provide Specialty Pharmacy Services for Improved Patient Outcomes and Lower Payer Costs

Retrieved on: 
Tuesday, August 3, 2021
Technology, Hospitals, Other Technology, Software, Practice Management, Managed care, Health, Pharmaceutical, Data management, Health sciences, Life sciences, Health care, Pharmacy, Specialty drugs, Clinical pharmacology, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Specialty pharmacy, Adherence, Prescription drug

Dea Belazi, president and CEO, AscellaHealth, says, “This exciting partnership will support advances in specialty medication compliance and foster a high level of plan member satisfaction -- while helping payers rein in the staggering costs of specialty drugs.”

Key Points: 
  • AscellaHealth , a global specialty pharmacy and healthcare solutions company, today announces a partnership with Appro-Rx , a national prescription benefit management company, to become its specialty pharmacy services and solutions provider.
  • Specialty drugs are vastly more expensive than their traditional drug counterparts, and this partnership not only enables our clients to realize significant cost savings but also to improve health outcomes for their employees.
  • AscellaHealths innovative specialty pharmacy and infusion services provide cost-saving discounts on prescription medications with timely access to therapies, data-driven reporting and patient support programsall of which help to improve patient adherence and health outcomes, thereby optimizing the patient journey.
  • AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services.

Antibe Therapeutics Provides Clinical Update for Otenaproxesul

Retrieved on: 
Tuesday, August 3, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Pain, Health, Antibe Therapeutics, Otenaproxesul, Medical statistics, Forward-looking statement, Clinical trial

The study is one of several nonclinical and clinical studies being conducted in advance of otenaproxesuls planned Phase III program.

Key Points: 
  • The study is one of several nonclinical and clinical studies being conducted in advance of otenaproxesuls planned Phase III program.
  • In parallel, Antibe will discuss the status of the AME study and the development path going forward with Health Canada.
  • Patient safety is paramount to Antibe in developing clinically relevant and novel medicines to control pain and inflammation.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.